Is early treatment of anaemia with epoetin-α beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial

Nephrology Dialysis Transplantation

Volumn 22, Issue 3, 2007, Pages 784-793

  Macdougall, Iain C ^a   Temple, R Mark ^b   Kwan, Jonathan T C ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Chronic kidney disease; Early treatment; Epoetin ; Pre dialysis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART LEFT VENTRICLE MASS; HEMATEMESIS; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PRURITUS; PURE RED CELL ANEMIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847647055     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl483     Document Type: Article

References (21)

1. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38 [4 Suppl 1]: S26-S29
2. Erslev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997; 51: 622-630
3. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 2001; 17: 629-636
4. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
5. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928-1936
6. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256
7. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
8. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000; 15 [Suppl 3]: 23-28
9. Besarab A, Ross RP, Nasca TJ. The use of recombinant human erythropoietin in predialysis patients. Curr Opin Nephrol Hypertens 1995; 4: 155-161
10. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in haemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
11. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-1430
12. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1182-1187
13. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156
14. Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811
15. Eckardt KU, MacDougall I, Locatelli F et al. Effects of epoetin beta on left ventricular mass in patients with chronic kidney disease: echocardiographic results from the CREATE study. J Am Soc Nephrol 2005; 16: 37A, THFC 172
16. Historical review of predialysis chronic renal function patients in order to assess the possibility of predicting anaemia by simple laboratory parameters. Janssen-Cilag. Data on file, 1997
17. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: Ii1-ii47
18. Gabrilove J. Overview: Erythropoiesis, anemia, and the impact of erythropoietin. Semin Hematol 2000; 37 [4 Suppl 6]: 1-3
19. Savino R, Ciliberto G. A paradigm shift for erythropoietin: No longer a specialized growth factor, but rather an all-purpose tissue-protective agent. Cell Death Differ 2004; 11 [Suppl 1]: S2-S4
20. Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003; 14 [7 Suppl 2]: S173-S177
21. Gouva C, Nikolopoulos P, Ioannidis JPA et al. Treating anaemia early in renal failure patients slows the decline of renal function; A randomised controlled trial. Kidney Int 2004; 66: 753-760